The excitement surrounding Moderna and Merck’s personalized mRNA cancer vaccine added more than $50 billion in combined market value to the two drug companies. That is the headline, and it is a genuinely hopeful one. But the Journal’s Heard on the Street column this weekend points at something less obvious happening underneath it: a gold rush in a corner of healthcare almost nobody was watching, which is tumor sequencing.
The logic is mechanical. A personalized cancer therapy is personalized because it is built for one patient’s specific tumor. To do that, the tumor has to be sequenced first, so you know which mutations the vaccine should target. No sequencing, no therapy. If these treatments become blockbusters, the diagnostic companies doing that work could hold what the column calls a lucrative tollbooth on every dose.
The anomaly worth understanding
Two companies sit at the center: Tempus AI and Personalis, the latter already involved in sequencing for Moderna’s clinical program. On July 20, Tempus agreed to acquire Personalis at $16.25 a share, a deal valued around $1.5 billion net of the stake it already held. Weeks later, when Merck and Moderna reported positive late-stage melanoma results, Tempus stock surged 24%.
Then something unusual happened. Personalis shares shot past the acquisition price, reaching as high as $18. This is worth pausing on, because it inverts the normal pattern. A company being acquired usually trades at a slight discount to the agreed price, because there is always some risk the deal falls apart, and that risk has to be compensated. A premium says the opposite — that investors are betting on a sweetened offer or a bidding war. The newly released proxy gave reason to think so: Personalis had entertained multiple suitors, including a verbal proposal of $17 a share, before agreeing to the Tempus deal. Analysts have speculated that rival diagnostics companies could be among the interested parties.
Why this is a lesson rather than a tip
Because the honest version of the story includes the part that gets left out of the excitement. The mRNA cancer-treatment space is no sure bet. Just weeks after Moderna’s positive news, a rival suffered a setback in a mid-stage colorectal cancer vaccine trial. Plenty remains unknown, including whether pharmaceutical companies might eventually bring sequencing in-house or split the work among competing labs — which would collapse the tollbooth entirely. The estimates span an order of magnitude: at least $50 million in annual sequencing revenue if the vaccine is approved for melanoma, potentially more than $600 million if the approach extends to lung, bladder and kidney cancers.
That range is the whole point. When the plausible outcomes differ by a factor of twelve, you are not looking at an investment with a knowable value. You are looking at a set of scenarios with a price attached. Some of them are excellent. Reasonable people can own that, at a size where being wrong is survivable. What nobody should do is mistake a compelling narrative for a resolved question, and the surest sign of that mistake is a position sized as though the good outcome is already settled.
There is a broader planning point that applies well beyond biotech, and it comes up constantly in this office. People frequently want to invest in a story they believe in — a cure, a technology, an industry they know from the inside. That instinct is not wrong, and the knowledge is often real. The failure is almost never in the thesis. It is in the sizing, because conviction quietly substitutes for arithmetic.
The practical rule is unromantic: decide what share of the portfolio you could lose entirely without changing your retirement date, and let a thematic position live inside that number. If you are holding something in this space, or thinking about it, that is a fifteen-minute conversation worth having before the next set of trial results rather than after.